Publicaciones científicas

9 Publicaciones científicas disponibles

  • Endoscopical and pathological dissociation in severe colitis induced by immune-checkpoint inhibitors

    13 de mayo de 2020 | Revista: Oncoimmunology

    Carlos Eduardo de Andrea  1 , Jose Luis Perez-Gracia  2 , Eduardo Castanon  2 , Mariano Ponz-Sarvise  2 , Jose I Echeveste  1 , Ignacio Melero  3 , Miguel F Sanmamed  2 , Maria Esperanza Rodriguez-Ruiz  2

    (1) Department of Pathology, Clinica Universidad de Navarra (CUN), Pamplona, Spain.
    (2) Department of Oncology, Clinica Universidad de Navarra (CUN), Pamplona, Spain.
    (3) Department of Immunology, Clinica Universidad de Navarra (CUN), Pamplona, Spain.


  • CXCR1 and CXCR2 Chemokine Receptor Agonists Produced by Tumors Induce Neutrophil Extracellular Traps that Interfere with Immune Cytotoxicity

    6 de abril de 2020 | Revista: Immunity

    Teijeira Á (1), Garasa S (2), Gato M (3), Alfaro C (4), Migueliz I (2), Cirella A (2), de Andrea C (5), Ochoa MC (6), Otano I (3), Etxeberria I (3), Andueza MP (7), Nieto CP (2), Resano L (7), Azpilikueta A (4), Allegretti M (8), de Pizzol M (8), Ponz-Sarvisé M (9), Rouzaut A 6, Sanmamed MF 6, Schalper K 10, Carleton M (11), Mellado M (12), Rodriguez-Ruiz ME ()6, Berraondo  P (6), Perez-Gracia JL (7), Melero I (13).

    (1) Program for Immunology and Immunotherapy Department, CIMA, Universidad de Navarra, 31008 Pamplona, Spain; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain; Navarra Institute for Health Research (IDISNA), 31008 Pamplona, Spain.
    (2) Program for Immunology and Immunotherapy Department, CIMA, Universidad de Navarra, 31008 Pamplona, Spain.
    (3) Program for Immunology and Immunotherapy Department, CIMA, Universidad de Navarra, 31008 Pamplona, Spain; Navarra Institute for Health Research (IDISNA), 31008 Pamplona, Spain.
    (4 Program for Immunology and Immunotherapy Department, CIMA, Universidad de Navarra, 31008 Pamplona, Spain; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.
    (5) Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain; Navarra Institute for Health Research (IDISNA), 31008 Pamplona, Spain; Department of Oncology, Clinica Universidad de Navarra, 31008 Pamplona, Spain.
    (6) Program for Immunology and Immunotherapy Department, CIMA, Universidad de Navarra, 31008 Pamplona, Spain; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain; Navarra Institute for Health Research (IDISNA), 31008 Pamplona, Spain.
    (7) Department of Oncology, Clinica Universidad de Navarra, 31008 Pamplona, Spain.
    (8) Dompé Farmaceutici S.p.A., 20122 Milano, Italy.
    (9) Navarra Institute for Health Research (IDISNA), 31008 Pamplona, Spain; Department of Oncology, Clinica Universidad de Navarra, 31008 Pamplona, Spain.
    (10) Department of Pathology, Yale University School of Medicine, New Haven, CT 06520, USA.
    (11) Bristol Myers Squibb, Lawrence Township, NJ 08648, USA.
    (12) Chemokine Signaling Group, Department of Immunology and Oncology, Centro Nacional de Biotecnología (CNB-CSIC), 28049 Madrid, Spain.
    (13) Program for Immunology and Immunotherapy Department, CIMA, Universidad de Navarra, 31008 Pamplona, Spain; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain; Navarra Institute for Health Research (IDISNA), 31008 Pamplona, Spain.


  • Cellular cytotoxicity is a form of immunogenic cell death

    8 de marzo de 2020 | Revista: Journal Immunotherapy Cancer

    Minute L (1,2), Teijeira A (1,2,3), Sanchez-Paulete AR (1,2), Ochoa MC (1,2,3), Alvarez M (1,2), Otano I (1,2), Etxeberrria I (1,2), Bolaños E (1,2), Azpilikueta A (1,2), Garasa S (1,2), Casares N (1,2), Luis Perez Gracia J (2,4), Rodriguez-Ruiz ME (1,2,4), Berraondo P (5,2,3), Melero I (5,2,3,4).

    (1) Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain.
    (2) Navarra Institute for Health Research (IDISNA), Pamplona, Spain.
    (3) Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.
    (4) Departments of Oncology and Immunology, Clínica Universidad de Navarra, Pamplona, Spain.
    (5) Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain.


  • Immunotherapeutic effects of intratumoral nanoplexed poly I:C

    2 de mayo de 2019 | Revista: Journal for Immunotherapy of Cancer

    M Angela Aznar  1 , Lourdes Planelles  2 , Mercedes Perez-Olivares  2 , Carmen Molina  3 , Saray Garasa  3 , Iñaki Etxeberría  3 , Guiomar Perez  3 , Inmaculada Rodriguez  3 , Elixabet Bolaños  3 , Pedro Lopez-Casas  2 , Maria E Rodriguez-Ruiz  3 , Jose L Perez-Gracia  4   5   6 , Ivan Marquez-Rodas  7 , Alvaro Teijeira  3   5   6 , Marisol Quintero  2 , Ignacio Melero  8   9   10   11

SOLICITE